Conover C A, Powell D R
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.
Endocrinology. 1991 Aug;129(2):710-6. doi: 10.1210/endo-129-2-710.
Insulin-like growth factor-I (IGF-I) initiates its diverse biological effects by binding to type I IGF receptors on cells. In addition, IGF-I associates with distinct proteins that can modulate its actions. One of these IGF-binding proteins, IGFBP-3, is the major circulating form in adults and is produced by many cells in culture. We investigated the effect of purified bovine IGFBP-3 on IGF-I binding and IGF-I stimulation of amino acid uptake and DNA synthesis in cultured bovine fibroblasts, a cell culture system highly suitable for these types of studies. Incubation of cells with IGF-I resulted in time- and dose-dependent decreases in [125I]IGF-I binding and IGF-I stimulated [3H]aminoisobutyric acid uptake and [3H]thymidine incorporation. Preincubation with 4 nM IGF-I resulted in a 50-60% decrease in IGF-I receptor binding, accompanied by marked decreases in IGF-I-stimulated [3H]aminoisobutyric acid uptake (50-60%) and [3H]thymidine incorporation (80-90%). Preincubation with the IGF-I analog [QAYL]IGF-I (4 nM) or with 100 nM insulin, growth factors that bind and activate type I IGF receptor signalling but have little or no affinity for IGFBP-3, had effects comparable to IGF-I, decreasing both IGF-I binding and action 50-95%. The addition of IGFBP-3 during the preincubation period with IGF-I blocked the decrease in receptor availability and prevented the cells from becoming desensitized. IGFBP-3 did not prevent the [QAYL]IGF-I- or insulin-induced receptor loss and cellular resistance to IGF-I. These data indicate that IGFBP-3 can prevent IGF-I-induced receptor down-regulation, a process that renders cells refractory to further stimulation by IGF-I. Thus, cell-derived IGFBP-3 may function in a buffering capacity to restrict IGF-I and target cell interaction, thereby modulating the biological response to changes in local IGF-I levels.
胰岛素样生长因子-I(IGF-I)通过与细胞上的I型IGF受体结合来启动其多种生物学效应。此外,IGF-I还与不同的蛋白质结合,这些蛋白质可以调节其作用。其中一种IGF结合蛋白IGFBP-3是成年人循环中的主要形式,并且在培养的许多细胞中都能产生。我们研究了纯化的牛IGFBP-3对培养的牛成纤维细胞中IGF-I结合以及IGF-I刺激的氨基酸摄取和DNA合成的影响,牛成纤维细胞培养系统非常适合这类研究。用IGF-I孵育细胞导致[125I]IGF-I结合以及IGF-I刺激的[3H]氨基异丁酸摄取和[3H]胸苷掺入呈时间和剂量依赖性降低。用4 nM IGF-I预孵育导致IGF-I受体结合减少50 - 60%,同时IGF-I刺激的[3H]氨基异丁酸摄取(50 - 60%)和[3H]胸苷掺入(80 - 90%)显著降低。用IGF-I类似物[QAYL]IGF-I(4 nM)或100 nM胰岛素预孵育,这两种生长因子能结合并激活I型IGF受体信号传导,但对IGFBP-3几乎没有或没有亲和力,其作用与IGF-I相当,使IGF-I结合和作用降低50 - 95%。在与IGF-I预孵育期间加入IGFBP-3可阻止受体可用性的降低,并防止细胞脱敏。IGFBP-3不能阻止[QAYL]IGF-I或胰岛素诱导的受体丧失以及细胞对IGF-I的抗性。这些数据表明,IGFBP-3可以防止IGF-I诱导的受体下调,这一过程会使细胞对IGF-I的进一步刺激产生不应性。因此,细胞来源的IGFBP-3可能具有缓冲能力,以限制IGF-I与靶细胞的相互作用,从而调节对局部IGF-I水平变化的生物学反应。